Back to search
Palmar-plantar Erythrodysesthesia (PPE)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Palmar-plantar Erythrodysesthesia (PPE) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Palmar-plantar Erythrodysesthesia (PPE) trials you may qualify forThe palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin tre…
RATIONALE: F511 cream may prevent or reduce palmar-plantar erythrodysesthesia in women receiving doxorubicin hydrochloride liposome for metastatic breast cancer…
The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the fr…
The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-…
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a 25%-50% of patients treated with several commonly used anti-cancer d…